Please login to the form below

Not currently logged in
Email:
Password:

trametinib

This page shows the latest trametinib news and features for those working in and with pharma, biotech and healthcare.

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Proactive adjuvant treatment could extend melanoma patient lives. England’s cost effectiveness watchdog NICE has recommended the use of Novartis’ Tafinlar (dabrafenib and Mekinst (trametinib) combination in melanoma. ... Clinical trial results showed

Latest news

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    The EMA has approved Tafinlar (dabrafenib) and Mekinist (trametinib) for the adjuvant (post-surgery) treatment of stage III melanoma patients with BRAF V600 mutations, following in the footsteps of the US

  • Novartis scores but Roche misses in melanoma trials Novartis scores but Roche misses in melanoma trials

    The combination of Novartis BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) met its objective with a 53% reduction in death or disease recurrence in the COMBI-AD trial, which ... Both ipilimumab and the combination of

  • Novartis gets lung cancer OK for Tafinlar/Mekinist combo Novartis gets lung cancer OK for Tafinlar/Mekinist combo

    The European Commission has cleared BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) for patients with advanced or metastatic NSCLC whose tumours bear the BRAF V600 mutation.

  • J&J gets CHMP backing for broader Darzalex use J&J gets CHMP backing for broader Darzalex use

    CHMP round-up. At its meeting last week the CHMP also gave its blessing to the combination of Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive non-small cell lung

  • The UK's new Cancer Drugs Fund The UK's new Cancer Drugs Fund

    Gaining the greenlight were Novartis' Zykadia (ceritinib) for lung cancer and melanoma combination Tafinlar (dabrafenib) and Mekinist (trametinib), and Servier's Lonsurf (trifluridine/tipiracil HCl) for bowel cancer.

More from news
Approximately 7 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics